ZIDOVUDINE SENSITIVITY OF HUMAN IMMUNODEFICIENCY VIRUSES FROM HIGH-RISK, SYMPTOM-FREE INDIVIDUALS DURING THERAPY
ZIDOVUDINE SENSITIVITY OF HUMAN IMMUNODEFICIENCY VIRUSES FROM HIGH-RISK, SYMPTOM-FREE INDIVIDUALS DURING THERAPY
复制标题
DOI：
10.1016/0140-6736(90)93391-2
复制
发表时间：
1990-09-08
期刊：
影响因子：
168.9
通讯作者：
LARDER, BA
中科院分区：
文献类型：
--
作者：
BOUCHER, CAB;TERSMETTE, M;LARDER, BA
从18例接受齐多夫定治疗2年的最初无病毒感染的男性中分离出的人类免疫缺陷1型菌株进行了药物敏感性研究。开始时，所有的男性都有持续的核心抗原血症;在研究期间，有6人发展为获得性免疫缺陷综合征。聚合酶链反应用于检测逆转录酶215位残基的突变，这是一种与药物敏感性降低相关的突变。2年后，16/18株分离株发生突变。然而，在治疗约6个月后，仅在7个分离株中检测到突变，其中4个来自随后患有艾滋病的个体。与遗传数据相关的直接病毒敏感性数据有限。215突变的出现率似乎与CD 4计数和病毒毒力相关。
Human immunodeficiency type 1 isolates from 18 initially symptom-free men who were treated with zidovudine for 2 years were investigated for drug sensitivity. At the start all the men had persistent core antigenaemia; the acquired immunodeficiency syndrome developed in 6 during the study. The polymerase chain reaction was used to detect mutations at residue 215 of reverse transcriptase, a mutation associated with reduced drug sensitivity. After 2 years 16/18 isolates were mutant. However, after about 6 months of treatment the mutation was detected in only 7 isolates, 4 from individuals who subsequently had AIDS. Limited direct virus sensitivity data correlated with the genetic data. The rate of appearance of the 215 mutation seemed to correlate with CD4 counts and viral virulence.